LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study

ConclusionPt subgroups defined as PD-L1 –high by all 3 IHC assays (SP142, 22C3, SP263) had similar OS and PFS benefit with atezo, despite the different assay sensitivities and scoring algorithms. Enrichment in clinical benefit, favouring atezo, was also seen in bTMB positive subgroups. Atezo monotherapy is a potential new 1L tx option f or pts with PD-L1–high NSCLC. Table: LBA1SubgroupMedian OSHRaa (95% CI)AtezoChemonmonmoVENTANA SP142 (n  = 554)TC1/2/3 or IC1/2/3 WT27717.527714.10.83(0.65, 1.07)TC3 or IC3 WT10720.29813.10.59(0.40, 0.89)Dako 22C3 (n = 534)22C3 BEP26817.526614.10.82(0.64, 1.06)≥ 50% TPS13420.212611.00.60(0.42, 0.86)≥ 1% TPS21317.820114.00.73(0.55, 0.97)VENTANA SP263 (n = 546)SP263 BEP27117.227514.9 0.85(0.66, 1.09)≥ 50% TC15019.514316.10.71(0.50, 1.00)≥ 1% TC21217.821014.00.77(0.58, 1.02)Foundation Medicine bTMB (n = 389)bTMB BEP19613.319315.30.98(0.74, 1.30)≥ 109211.28310.30.87(0.58, 1.30)≥ 164213.9458.50.75(0.41, 1.35)≥ 202717.22910.50.77(0.36, 1.64)aStratified OS HRs for SP142 only.Clinical trial identificationNCT02409342.Editorial acknowledgementMedical writing assistance for this abstract was provided by Kia C. E. Walcott, PhD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.Legal entity responsible for the studyF. Hoffmann-La Roche.FundingF. Hoffmann-La Roche.DisclosureR.S. Herbst: Advisory / Consultancy: Abbvie Pharmaceuticals; Advisory / Consultancy: ARMO Biosciences; Advisory / Consultancy, Researc...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research